Lexaria Bioscience (LEXX) Price & Analysis

Compare

238 Followers

LEXX Stock Chart & Stats

$0.62

-$0.08(-3.57%)

At close: Jan 08 4:00 PM EST

$0.62

-$0.08(-3.57%)

Day’s Range― - ―

52-Week Range$0.77 - $2.43

Previous CloseN/A

Volume56.77K

Average Volume (3M)986.05K

Market Cap

$15.43M

Enterprise Value$14.19M

Total Cash (Recent Filing)$4.63M

Total Debt (Recent Filing)$116.59K

Price to Earnings (P/E)―

Beta0.73

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.58

Shares Outstanding24,887,445

10 Day Avg. Volume354,178

30 Day Avg. Volume986,050

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.92

Enterprise Value/Revenue23.04

Enterprise Value/Gross Profit23.14

Enterprise Value/Ebitda-1.25

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentsLexaria is now searching for a pharmaceutical partner to advance the clinical program for DehydraTECH-liraglutide, which could lead to significant developments in its clinical pathway.

Market AdoptionImprovement in GLP-1 drugs’ safety profile could lower patient dropout rates and enhance market adoption.

Safety And TolerabilityDehydraTECH-semaglutide has demonstrated a favorable safety and tolerability profile.

Bears Say

Analyst RecommendationAnalyst's recommendation adjusts the 12-month price target to $5 from $7.

Commercial SuccessDehydraTECH formulations need to demonstrate a comparable level of efficacy to marketed GLP-1 drugs to be commercially successful.

Efficacy ComparisonInterim efficacy results are not as robust as Rybelsus.

Lexaria Bioscience News

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase...

3d ago

LEXX

Lexaria Bioscience prices 2.66M share at the market offering at $1.315

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Published first on TheFly...

11d ago

LEXX

Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026

Lexaria Bioscience ( ($LEXX) ) just unveiled an update. Lexaria reported that its Phase 1b, 12‑week chronic study...

3d ago

LEXX

Lexaria Bioscience Secures $3.5 Million in Direct Offering to Boost R&D

The latest update is out from Lexaria Bioscience ( ($LEXX) ). Lexaria Bioscience Corp. announced a $3.5 million...

11d ago

LEXX

Lexaria Extends Agreement to Advance Drug Delivery Technology Evaluation

The latest announcement is out from Lexaria Bioscience ( ($LEXX) ). Lexaria Bioscience Corp. has extended its Material...

1M ago

LEXX

Lexaria Bioscience extends material transfer agreement with pharma company

Lexaria Bioscience (LEXX) provided an update on the Material Transfer Agreement originally entered into on September 4, 2024...

1M ago

LEXX

Lexaria Bioscience files to sell 2.76M shares of common stock for holders

The company will not receive any proceeds from the sale of shares of common stock by the selling...

2M ago

LEXX

Lexaria Bioscience Expands Strategic Outreach and Secures New Patents

Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience Corp. has engaged a global life science...

3M ago

LEXX

Lexaria Bioscience engages advisory firm to identify new business opportunities

The company said, “For several years, Lexaria has been validating the applicability of its patented DehydraTECH technology across...

3M ago

LEXX

Lexaria Bioscience Secures $4 Million for R&D Expansion

Lexaria Bioscience ( ($LEXX) ) has provided an update. Lexaria Bioscience Corp. announced the successful closing of a...

3M ago

LEXX

Lexaria Bioscience announces $4M registered direct offering priced ATM

Lexaria Bioscience (LEXX) announced that it has entered into a definitive agreement for the purchase and sale of...

3M ago

LEXX

Lexaria Bioscience prices 2.7M shares at $1.50 in registered direct offering

Lexaria Bioscience (LEXX) entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667...

3M ago

LEXX

Lexaria Bioscience Ends Capital on Demand Agreement

An announcement from Lexaria Bioscience ( ($LEXX) ) is now available. On September 19, 2025, Lexaria Bioscience Corp....

3M ago

LEXX

Lexaria Bioscience’s DehydraTECH Boosts Semaglutide Brain Delivery

Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience has announced promising results from a study...

3M ago

LEXX

LEXX FAQ

What was Lexaria Bioscience’s price range in the past 12 months?

Lexaria Bioscience lowest stock price was $0.77 and its highest was $2.43 in the past 12 months.

What is Lexaria Bioscience’s market cap?

Lexaria Bioscience’s market cap is $15.43M.

When is Lexaria Bioscience’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Lexaria Bioscience’s earnings last quarter?

Currently, no data Available

Is Lexaria Bioscience overvalued?

According to Wall Street analysts Lexaria Bioscience’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lexaria Bioscience pay dividends?

Lexaria Bioscience does not currently pay dividends.

What is Lexaria Bioscience’s EPS estimate?

Lexaria Bioscience’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lexaria Bioscience have?

Lexaria Bioscience has 24,887,445 shares outstanding.

What happened to Lexaria Bioscience’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Lexaria Bioscience?

Currently, no hedge funds are holding shares in LEXX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.